| Name | 4-[5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benze nesulfonamide |
|---|---|
| Synonyms |
4-[3-(4-methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide
4-[3-(4-Methoxyphenyl)-1-propyl]piperidine Benzenesulfonamide, 4-[4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl]- 4-[5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benzenesulfonamide Piperidine,4-[3-(4-methoxyphenyl)propyl] 4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide ML-141 ML141 |
| Description | ML141(CID-2950007) is a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase(IC50=200 nM) with low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). IC50 value: 200 nM [1]Target: Cdc42 inhibitorin vitro: In the primary HTS bead-based assay using 1 mM EDTA and 100 nM BODIPY-FL-GTP, potency for CID2950007 was IC50 = 2.6 and 5.4 μM for Cdc42 wild type and activated mutant, respectively [1]. ML141 exposure also enhanced the ability of TMX to suppress BLBC cell growth, through both induction of cell death and suppression of cell division [2]. in vivo: Treatment with ML141 + TMX caused a suppression of further tumour growth in vivo [2]. Parallel suppression of the conserved brain CDC42 activity by intracerebroventricular ML141 injection caused acute anxiety in mice [3]. using a pilocarpine-induced epileptic model, we found that pretreatment with ML141, a specific inhibitor of Cdc42, reduces seizure severity [4]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 622.9±65.0 °C at 760 mmHg |
| Melting Point | 216 °C |
| Molecular Formula | C22H21N3O3S |
| Molecular Weight | 407.485 |
| Flash Point | 330.5±34.3 °C |
| Exact Mass | 407.130371 |
| PSA | 93.37000 |
| LogP | 1.82 |
| Appearance | white to beige |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.652 |
| Storage condition | 2-8°C |
| Water Solubility | DMSO: soluble5mg/mL (warmed, clear solution) |
| Hazard Codes | Xi |
|---|---|
| RIDADR | NONH for all modes of transport |
|
~66%
71203-35-5 |
| Literature: Faid-Allah, Hassan M.; Mokhtar, Hassan M. Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1988 , vol. 27, # 1-12 p. 245 - 249 |
|
~64%
71203-35-5 |
| Literature: Feid-Allah Pharmazie, 1981 , vol. 36, # 11 p. 754 - 756 |
|
~71%
71203-35-5 |
| Literature: Faid-Allah, Hassan M.; Mokhtar, Hassan M. Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1988 , vol. 27, # 1-12 p. 245 - 249 |
|
~%
71203-35-5 |
| Literature: Faid-Allah, Hassan M.; Mokhtar, Hassan M. Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1988 , vol. 27, # 1-12 p. 245 - 249 |
|
~%
71203-35-5 |
| Literature: Faid-Allah, Hassan M.; Mokhtar, Hassan M. Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1988 , vol. 27, # 1-12 p. 245 - 249 |